← Back to Clinical Trials
Recruiting NCT05132517

NCT05132517 Magnesium and Cognition After Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05132517
Status Recruiting
Phase
Sponsor BDH-Klinik Hessisch Oldendorf
Condition Stroke
Study Type OBSERVATIONAL
Enrollment 80 participants
Start Date 2022-10-26
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Kölner Neuropsychologische Screening für Schlaganfall-Patienten

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 80 participants in total. It began in 2022-10-26 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cognitive impairments such as memory impairments, word-finding difficulties, compromised orientation and perception are often observed in stroke patients. Low serum-mg-concentrations are associated with cognitive impairments in ischemic stroke patients one month after stroke onset. It is not clear, if cognitive impairments after stroke is caused by the mg-deficiency or by the stroke itself. Until now, no studies investigating the relationship between mg-concentration, stroke severity and cognition during treatment course are available. Thus, this study aimed to investigate the relationship between mg-concentration and cognition of stroke patients.

Eligibility Criteria

Inclusion Criteria: * ischemic/hemmorhagic stroke * written consent form Exclusion Criteria: * pre-existing dementia or cognitive impairment before stroke onset * pre-existing mental disorder (depression) or present/prior long-term treatment (\> 6 months) with psychotropic drugs * pre-existing malign tumor disease * participation in another clinical trial within the past 30 days * pregnancy or breastfeeding

Contact & Investigator

Central Contact

Simone B Schmidt, Dr.

✉ si.schmidt@nkho.de

📞 0049 5152 781 215

Principal Investigator

Simone B Schmidt, Dr.

PRINCIPAL INVESTIGATOR

BDH-Clinic Hessisch Oldendorf

Frequently Asked Questions

Who can join the NCT05132517 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05132517 currently recruiting?

Yes, NCT05132517 is actively recruiting participants. Contact the research team at si.schmidt@nkho.de for enrollment information.

Where is the NCT05132517 trial being conducted?

This trial is being conducted at Hessisch Oldendorf, Germany.

Who is sponsoring the NCT05132517 clinical trial?

NCT05132517 is sponsored by BDH-Klinik Hessisch Oldendorf. The principal investigator is Simone B Schmidt, Dr. at BDH-Clinic Hessisch Oldendorf. The trial plans to enroll 80 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology